Search
Menu
Home
HTB
2009
February
09
9 February 2009
Contents
Antiretrovirals
Maraviroc safety label changes included with US traditional approval
US approval of paediatric abacavir
EMEA supports extension of D:A:D study until at least 2012 and the new remit to include non-AIDS cancers and kidney disease
Applications to approve non-refrigerated ritonavir submitted to EMEA and FDA
PK and drug interactions
Elvitegravir with tipranavir/ritonavir or darunavir/ritonavir
Serum bilirubin increases when PEG-interferon and ribavirin are used with atazanavir
Drug interactions with integrase inhibitors
Drug interactions between efavirenz and itraconazole
Effect on tacrolimus when switching from nelfinavir to fosamprenavir
HTB RSS
Early access
Long-acting CAB/RPV in people with suboptimal adherence: IMPALA study results at 48 weeks
17 July 2025
Potential for once-monthly oral PrEP using MK-8527
17 July 2025
Five doses a week could be a safe option for adults: crisis response to ART stock-outs
16 July 2025
5-on 2-off dosing is inferior to continuous ART in BREATHER Plus – but no difference in clinical outcomes
16 July 2025
All early access reports
Current issues
July 2025
June 2025
May 2025
Back issues
Special report
AIDS quilts at the Tate: reflection and also anger
8 July 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate